×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Bladder Cancer
Kristie L. Kahl
The combination of Padcev plus Keytruda induced a high rate of durable objective response rates in patients with locally advanced or metastatic urothelial cancer.
Kristie L. Kahl
A new study supported the use of a blood test to detect clusters of cancer cells in the blood of asymptomatic individuals, meaning, patients could have a non-invasive screening and testing method.
Katie Kosko
Better response rates may be seen in patients with advanced bladder cancer when two therapies are combined.
The Bladder Cancer Advocacy Network announces it's Bladder Cancer Research Innovation Award.
FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.
Bladder Cancer Advocacy Network
The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2020 Young Investigator Awards (YIA), to support the development of outstanding early-career research scientists and clinical cancer research investigators.
Kristie L. Kahl
This new option may save patients with high-risk non-muscle invasive bladder cancer from having to undergo a radical cystectomy to treat their disease.
Bladder Cancer Advocacy Network
At 15 years old the Bladder Cancer Advocacy Network looks back and takes a look ahead.
Kristie L. Kahl
The Food and Drug Administration approved Keytruda for the treatment of patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer.
Kristie L. Kahl
Patients with previously untreated locally advanced or metastatic urothelial carcinoma treated with Bavencio and best supportive care as a first-line maintenance therapy experienced significantly longer survival.